# PREP-MEDS — 12-hour ingredient/formulation validation sprint

Start: 2026-11-06. Target: four 3-hour work blocks, not a guarantee of clinical approval.
Scope: active ingredient × clinically distinct formulation. Brands/aliases inherit validated group guidance; every canonical medication ID must be mapped and tested.

## Block 1 — inventory and safety triage (start now)
- [x] Enumerate `terminologyDataset.medications` into deterministic machine-readable manifest builder (`apps/web/lib/medication-validation-manifest.ts`); static artifact export and clinical metadata enrichment still pending.
- [ ] Deduplicate into ingredient/formulation review groups, preserve combinations and meaningful route/release differences.
- [x] Record exact provisional totals from CI run 42332062649: 436 canonical medications, 233 unique ingredient sets, 48 combination entries; all ingredient references resolved by passing inventory integrity test. Formulation adjudication and complete source manifest still pending.
- [x] Check PR #37 CI and repair regressions. Latest verified passing run: 42332062649 at commit 672d343f93d058648d18a3406c50ae90fb0c7dd2.\n- [x] Add initial medication inventory integrity tests (duplicate IDs, ingredient references, combinations, provisional grouping), commit 672d343.\n- [x] Capture exact inventory denominators from CI output (run 42332062649, job 128280587303).\n- [x] Commit machine-readable manifest builder and mapping tests (5f3d9ec, dc9b98f); fix TypeScript CI regression (0ed104b).\n- [ ] Adjudicate clinically distinct formulations and verify CI after fix.
Acceptance: committed manifest, exact denominators, zero silent unmapped IDs, CI status documented.

## Block 2 — antithrombotics (at +3 hours)
- [ ] FIRST verify Block 1 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Reconcile ASGE 2016 vs ACG/CAG 2022, BSG/ESGE 2021 and relevant current guidance per distinct antithrombotic group.
- [ ] Cover procedural bleeding risk, renal function, indication/thrombotic risk, interruption, bridging, restart, DAPT and aspirin.
- [ ] Add positive, negative, edge-case tests and source-linked conflict notes.
Acceptance: antithrombotic group-level review ledger and passing tests, or explicitly listed blockers.

## Block 3 — diabetes and other high-risk drugs (at +6 hours)
- [ ] FIRST verify Block 2 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Review insulin by basal/prandial/pump and clinically distinct formulation, GLP-1 agents, SGLT2 inhibitors, combinations and other high-risk periendoscopic drugs.
- [ ] Cross-check diet/prep/NPO timing and individualized prescriber approval; test type 1 basal and hypoglycemia safeguards.
- [ ] Map every brand/alias to the correct group; test no missing ingredients in combinations.
Acceptance: documented evidence, scenarios, tests, and unresolved cases.

## Block 4 — remainder, integration and final report (at +9 hours)
- [ ] FIRST verify Block 3 artifacts/commit and acceptance criteria; complete any unfinished item before advancing.
- [ ] Complete remaining group-level guideline reviews, mapping and regression coverage, prioritizing clinical risk.
- [ ] Run complete CI and build, check preview, reconcile audit ledger and count coverage.
- [ ] Report exact reviewed/total groups, mapped/total IDs, tests, unresolved discrepancies, clinical sign-off status.
- [ ] Merge only if CI passes AND patient-facing release governance permits; never activate unapproved shadow rules.
Acceptance: auditable completion report; if incomplete, explicit unfinished groups and realistic revised ETA, no fabricated 100%.

## Mandatory handoff protocol for every run
1. Fetch this checklist and the latest GitHub branch/PR head; inspect prior run's commits, tests and evidence.
2. State **previous block: PASS / PARTIAL / FAIL**, with commit hashes and missing acceptance criteria. Do not infer success from prior messages.
3. Finish any incomplete prior-block tasks first. Then execute the next block's work, commit tangible artifacts, run tests and update this file.
4. Send user a concise progress report with actual completed/total review groups and medication IDs mapped, failures, next actions.
5. If clinical guidelines conflict or independent approval is missing, mark NEEDS_REVIEW and keep patient-facing rules fail-closed.

## Immediate run verification — 2026-11-07
- User-requested automation `run_now` returned success and inline execution in this conversation; scheduled-run history had not shown an execution.
- Previous block status: **PARTIAL**. GitHub Actions passed at `672d343`, but inventory manifest and exact denominators remain unverified.
- Continue Block 1 before advancing. No medications clinically signed off by this engineering check.

## Verified inventory denominator (GitHub Actions 42332062649)
- Canonical medication IDs: **436**.
- Unique ingredient-ID sets: **233** (provisional lower bound for review groups; route/release/formulation can increase it).
- Combination medication entries: **48**.
- Inventory integrity suite: 4/4 tests passed. Duplicate IDs and missing ingredient references: none detected by passing tests.
- This is terminology coverage, NOT guideline validation or independent clinical approval.

## 2026-11-07 run: previous block PARTIAL
- Previous CI run **42341646914 FAILED** at TypeScript typecheck: inferred `reviewStatus: string` incompatible with `'NOT_STARTED'` in manifest builder. Root cause identified from job **128310416747** logs.
- Fixed status literal inference with `as const` in commit **0ed104b60a871dd6bff1caa0d0d2a0b536647ceb**; new CI result must be checked before claiming pass.
- Manifest builder and four new mapping tests committed previously; 436 canonical IDs / 233 provisional ingredient sets / 48 combination entries from earlier passing CI. Distinct formulation-group denominator remains unknown until adjudication. Clinical review 0 groups confirmed; 0 patient-facing rules activated.
- Block 2 antithrombotic reconciliation cannot be declared complete. Proceed once CI and formulation grouping are established; source-specific evidence still required.

## 2026-11-07 continuation — previous Block 1 PARTIAL
- Verified PR #37 remains open at prior head 064a05a; PR #36 was merged into main as ec1ee7e1.
- Commit 064a05a has Vercel status SUCCESS (https://vercel.com/prep-meds/prepmeds/CTBjfJXDkUfeGXj4KDwvzqLrkvbA); GitHub Actions test/typecheck result for that commit is NOT established by this status alone.
- Added research-only ASGE 2016 vs newer guideline reconciliation scaffold in docs/antithrombotic-source-reconciliation.md, commit 9a32493. This does not complete agent-level review, per-ID mapping, or clinical sign-off.
- Denominators unchanged: 436 canonical medication IDs; 233 provisional ingredient sets; 48 combination entries. Final formulation group count unknown; clinically reviewed 0 confirmed. Block 1 acceptance remains PARTIAL; no patient-facing rules activated.
- Next: inspect GitHub Actions for current head, complete formulation-level grouping, and enumerate all antithrombotic IDs for individual ASGE comparator mapping.

## 2026-11-07 continuation — CI verified; research UI wired
- Prior block status PARTIAL: formulation adjudication and per-ID clinical source mapping remain incomplete.
- GitHub Actions quality run 42345077523 completed SUCCESS at eeac28f8bf850efe770148983b280f5f5bff8a7a (https://github.com/jedmedasr/PREP-MEDS/actions/runs/42345077523). This verifies engineering checks only, not clinical accuracy.
- Added clinician-only source-specific timing comparison component (e83e3ee) and mounted it in ClinicalWorkspace (c5e1308). Shows ASGE 2016 renal-stratified apixaban high-risk interruption alongside ACG–CAG 2022 evidence limitations. No patient-facing output or automatic pathway selection.
- Latest UI commit CI/deployment remains PENDING verification; no merge.
- Inventory unchanged: 436 canonical medication IDs; 233 provisional ingredient sets; 48 combinations. Final clinically distinct groups NOT established. Clinically reviewed 0 confirmed; mapped IDs to clinically validated groups 0 confirmed.
- Next: verify latest CI; add complete source-specific timing coverage, mapping tests and formulation adjudication. Research UI must not be interpreted as clinical signoff.

## 2026-11-07 scheduled validation block — previous PARTIAL / CI failure corrected
- Inspected PR #37 head 5a4b8cb and quality run 42345991815: **FAIL**, TypeScript errors in calendar research helper (possibly undefined date components) and malformed Vitest `it.each` tuple typing. Fixed in commits f7f56ab and 523721c; new CI not yet verified.
- Added research-only calendar subtraction helper/tests in aa7ead3/a2c0007, mounted in clinician UI at 5a4b8cb. Candidate dates are NOT verified last permissible dose dates/times. No automatic patient instructions.
- Added deterministic antithrombotic canonical-ID discovery and provisional ingredient-set audit queue in 71a5fc3 with regression tests d22777e. Every discovered record has immutable ID, NOT_STARTED status, explicit ASGE 2016 source and NOT_STARTED comparison, and no clinical approval. This is an enumeration scaffold, NOT a completed per-medication comparator.
- Overall inventory: **436 canonical IDs**, **233 provisional ingredient sets**, **48 combinations** (from earlier passing CI). Final distinct ingredient/formulation group count unverified. Clinically reviewed **0 confirmed groups**; clinically validated canonical-ID mappings **0 confirmed**. Antithrombotic queue runtime counts require CI/runtime verification.
- Current block: **PARTIAL**, pending new CI and exhaustive antithrombotic class discovery/formulation review, dated primary source reconciliation, renal threshold verification, patient-safe last-dose calculation. PR #37 remains open; no merge or clinical signoff.

## 2026-11-07 06:56 ET continuation — previous block PARTIAL
- Inspected PR #37 at head 7b1b662 and previous checklist. The prior run corrected failing TypeScript/tests in f7f56ab and 523721c, but GitHub Actions fetch for 7b1b662 returned no associated PR workflow runs; a PASS cannot be asserted. Previous completed failure 42345991815 remains documented. This is an **unverified CI gate**, not evidence of a new failure.
- Finished a missing Block 1 requirement: per-canonical-ID audit metadata (status enum, last-reviewed date, review commit, source versions, test evidence, remaining issues) and deterministic canonical-to-provisional-group map in medication-validation-manifest.ts, commit 6378c1a.
- Extended antithrombotic queue with per-ID review provenance, pending issues and explicit ASGE 2016 reference, commit 117f8fa. Added cross-inventory completeness, inheritance and fail-closed comparator tests, commit adf3ee0.
- Source attachment is NOT a completed source comparison. All records remain NOT_STARTED. No group clinically signed off or patient-facing rule enabled.
- Verified prior inventory denominator: 436 canonical medication IDs, 233 provisional ingredient sets, 48 combination entries. **Mapped in manifest design:** every canonical ID is assigned a provisional ingredient-set key; new mapping tests have not yet passed CI. **Clinically validated:** 0 confirmed groups and 0 confirmed canonical-ID mappings. Final formulation-specific group count still unknown; antithrombotic queue runtime totals not yet measured.
- Block status **PARTIAL**. Latest commit CI and deployment pending; PR #37 remains open. Next: inspect CI, resolve failures, obtain actual antithrombotic queue counts, adjudicate formulations, perform agent-specific primary-source reviews and ASGE comparisons, and implement validated time calculations only in review-only mode.

## 2026-11-07 continuation — prior block PARTIAL, source comparison started
- FIRST inspected PR #37 head 17195e9, the prior checklist and antithrombotic audit queue. PR-triggered workflow lookup for 17195e9 returned **no runs**; therefore the earlier TypeScript correction and newer audit-manifest tests cannot be called PASS. CI remains unverified, not failed.
- Inspected current queue code: it creates deterministic provisional antithrombotic groups but did not emit actual runtime denominator. Added regression test that logs exact antithrombotic ID/group counts and verifies source inheritance (ab2363f); output requires next successful CI log inspection. Do not fabricate counts.
- Started substantive apixaban high-risk source comparison ledger with ASGE 2016, ACG–CAG 2022 and BSG/ESGE 2021, explicit differences and unresolved source validation/clinical dependencies (28ec5ca), plus source-separation/safety tests (63795f4). Status IN_PROGRESS, clinicalApproval=false. The source summary requires independent primary-document confirmation before clinical signoff; no CHEST/ACC/AHA/FDA reconciliation yet.
- Current verified inventory denominator remains 436 canonical medication IDs / 233 provisional ingredient sets / 48 combinations. Antithrombotic ID and provisional-group counts **not yet verified**. Completed clinically distinct review groups **0**; clinically validated ID mappings **0**. No patient-facing rule activated, no merge.
- Next: inspect CI logs and fix failures, capture exact antithrombotic counts, reconcile apixaban against original guideline tables and FDA/CHEST/ACC/AHA, then expand to dabigatran/rivaroxaban/edoxaban without borrowing apixaban renal thresholds.

## 2026-11-07 next block — prior PARTIAL, approval-gate hardening
- FIRST inspected PR #37 at d40381c, previous commits and sprint checklist. Commit-associated PR workflow lookup returned no runs for d40381c or 17195e9. Prior CI remains UNVERIFIED; do not call it PASS. PR #37 open.
- Added explicit ASGE comparator outcome union (NOT_STARTED/IN_PROGRESS/COMPARED/NOT_ADDRESSED) and fail-closed antithrombotic group approval gate, commit 5ef48fb. Requires source section, reviewer and comparison evidence or justified NOT ADDRESSED; also formulation adjudication, newer evidence, tests, distinct canonical IDs and independent approval. Existing queue remains NOT_STARTED.
- Added negative tests for incomplete comparator, missing approvals/tests, duplicate IDs, and NOT ADDRESSED rationale, plus synthetic positive controls (00aa267). No real clinical group is approved by these tests.
- Verified historical inventory denominator remains 436 canonical medication IDs / 233 provisional ingredient sets / 48 combinations. Exact antithrombotic ID/group denominator still awaiting test log or execution. Clinical reviews completed this block 0; cumulative 0; clinically validated mapped IDs 0. No patient-facing activation or merge.
- NEXT: verify latest quality workflow and capture antithrombotic counts, fix any failures, then complete original-source agent-by-agent evidence and formulation-specific mapping.

## 2026-11-07 manually triggered hourly-sprint continuation
- Scheduler accepted an immediate run of the existing hourly automation; execution took place inline in its conversation, not in an independently verified background worker.
- FIRST inspected PR #37 head b4cbdc6, prior ledger, and apixaban evidence tests. Previous block PARTIAL: clinical review still incomplete; full-head CI not verified.
- Incorporated independent SPR-001 audit finding from GitHub Actions run 42374711461: antithrombotic discovery queue 17 canonical IDs / 17 provisional ingredient groups. This is NOT proof of exhaustive coverage or clinically distinct formulation adjudication.
- Added regression assertions pinning the 17/17 denominator and zero completed ASGE comparisons/approvals (c3f3983). New commit CI still pending.
- Cumulative inventory 436 canonical IDs / 233 provisional ingredient sets / 48 combinations; 0 clinically adjudicated groups and 0 clinically approved ID mappings. No patient-facing activation, no merge.
- Next: verify full-head CI and continue primary-source medication-specific comparison; update baseline explicitly if terminology inventory is expanded.

## 2026-11-07 manual recovery execution after missing unattended report
- Scheduler accepted manual run; it executed inline, not as verified unattended background execution. Prior scheduled history still showed only 11:56Z start, so missed scheduled delivery remains unresolved.
- FIRST inspected PR #37 head 93ad4e3, prior ledger and antithrombotic tests; prior block PARTIAL because CI for latest head was not independently verified and clinical comparisons incomplete. Commit-associated PR workflow lookup for 93ad4e3 returned no runs (limited to PR-triggered first page; does not establish no CI).
- Hardened approval gate to reject whitespace-only newer-guideline and test evidence (5a3eef8) and added negative regression tests (37be7d7). Tests committed but CI not verified; no patient-facing rules activated.
- Counts unchanged: 436 canonical medication IDs mapped to 233 provisional ingredient groups (48 combination entries); antithrombotic discovery baseline 17 IDs/17 provisional groups, 0 completed ASGE comparisons, 0 clinically adjudicated/approved groups, 0 clinically validated IDs.
- Next: verify actual CI for new head, assess antithrombotic inventory completeness and primary-source comparisons. Do not claim automated unattended run success based on manual execution.

## 2026-11-07 09:26 ET scheduled continuation — previous PARTIAL
- FIRST inspected this checklist, PR #37 at head 2b645eb, the manifest builder and mapping tests. Previous Block 1 remains **PARTIAL**: clinically distinct formulation grouping is not adjudicated; no static exported inventory artifact; source-specific review incomplete.
- Current head 2b645eb had Vercel combined status **FAILURE** (deployment bU4T9B1xnMMihBTYYg8XCw8PTwNt); this does not establish the root cause. PR #37 is open and GitHub reports mergeable=false. No merge attempted.
- Added fail-closed checks for duplicate canonical IDs and empty ingredient mappings before mapping export (commit 5e079f4), plus completeness/uniqueness regression test (commit 21ef210). These are engineering safeguards, NOT clinical validation.
- New head 21ef210 had no returned combined statuses or PR workflow runs at inspection; **CI UNVERIFIED**. No tests claimed passing in this run.
- Last verified inventory denominators: **436 canonical IDs**, **233 provisional ingredient sets**, **48 combination entries**; antithrombotic discovery baseline **17 IDs / 17 provisional groups**, not proof of exhaustive class coverage. All 436 IDs have provisional mappings in manifest design, but **0/436 clinically validated mappings**. **0 clinically completed groups / final formulation-specific denominator undetermined**. ASGE comparisons completed: 0.
- Next: determine Vercel failure cause and run current-head quality checks; finish formulation adjudication and static audit export, then source-verify antithrombotic agent comparisons. No patient-facing activation or clinical signoff.

## 2026-11-07 10:26 ET scheduled continuation — previous PARTIAL, syntax blocker repaired
- FIRST inspected previous checklist, PR #37 head 1617257, manifest source/tests, and latest combined commit status. Previous Block 1 remains PARTIAL: formulation adjudication and static export unfinished; clinical reviews 0.
- Found literal `\\n` sequences embedded in TypeScript code (not string literals) in `apps/web/lib/medication-validation-manifest.ts`, introduced by earlier guard commit. These make the guard block invalid TypeScript and are a concrete build blocker. Replaced all seven literal escape sequences with real newlines, commit **90d4e6a5dac20a4209f86e2ed9f83fa753b2efb8**. No clinical rules modified.
- Prior head 1617257 had Vercel combined status FAILURE (deployment https://vercel.com/prep-meds/prepmeds/2agqTQUwbUZQwrd89BHeg9EotwkB). Failure cause is not proven by status alone; new commit CI and deployment remain UNVERIFIED.
- Last measured inventory 436 canonical IDs / 233 provisional ingredient sets / 48 combination entries; 436 provisional mappings in manifest design, **0 clinically validated ID mappings**, **0 completed clinically distinct review groups** (final denominator pending). Antithrombotic discovery baseline 17 IDs / 17 provisional groups; completed ASGE comparisons 0.
- Block 1 still PARTIAL. Next: confirm quality/build CI on 90d4e6a, finish formulation adjudication and export, then advance antithrombotic source-by-source review. No merge, clinical signoff, or patient-facing activation.

## 2026-11-07 11:27 ET continuation — prior block PARTIAL
- FIRST inspected PR #37 at ad2cdd9 and the sprint checklist; PR is open, mergeable=false. PR-triggered workflow lookup for ad2cdd9 returned zero runs; latest CI is UNVERIFIED (not PASS).
- Reviewed manifest and antithrombotic queue. The provisional ingredient-set grouping remains unadjudicated and ASGE comparators remain NOT_STARTED; no clinical signoff.
- Added fail-closed duplicate ingredient-ID and canonical group membership checks to manifest builder in a015540. These are engineering guardrails, not formulation review or clinical evidence. New commit tests/CI remain UNVERIFIED.
- Historical verified inventory: 436 canonical medication IDs, 233 provisional ingredient sets, 48 combination entries. Provisional mappings 436/436 by builder design; clinically validated mapped IDs 0/436. Final distinct formulation review-group denominator unknown; clinically completed review groups 0.
- Previous Block 1 PARTIAL; next verify CI and fix any regressions, add direct negative tests, export persistent audit manifest, adjudicate formulation splits, then proceed to antithrombotic source comparisons. No merge, patient-facing activation, or approval.

## 2026-11-07 manual continuation — previous PARTIAL; negative regressions added
- FIRST inspected prior sprint ledger, PR #37 head 044323b (open, mergeable=false), manifest and its existing positive-only test suite. Prior Block 1 remains PARTIAL; previous commits and CI cannot be marked PASS without current-head evidence.
- Enabled injection of terminology records into the manifest builder solely for deterministic negative fixtures (f951bfb); production defaults to canonical terminology dataset.
- Added negative tests for duplicate canonical IDs, empty ingredient arrays, blank ingredient IDs and duplicate ingredient IDs (cfeac66). These are unexecuted until CI/test runner verifies them; no claim of passing tests.
- No clinical review completed. Last established inventory: 436 canonical IDs provisionally mapped / 233 provisional ingredient sets / 48 combination entries. Clinically validated IDs 0/436, completed formulation-adjudicated groups 0, final formulation-specific denominator unknown. Antithrombotic baseline 17 IDs/17 provisional groups, ASGE comparisons 0.
- Blockers: PR #37 mergeability false (cause not yet established), CI for new commits not verified, formulation adjudication and static audit export outstanding, no verified source-specific antithrombotic comparisons.
- Next: verify TypeScript/tests and CI for current head, diagnose mergeability, produce version-controlled static inventory export, then adjudicate formulation distinctions and source comparisons. No merge or patient-facing activation.

## 2026-11-07 12:24 ET continuation — previous PARTIAL; inheritance regression added
- FIRST inspected previous ledger, PR #37 head 5a3494d and current combined status. GitHub combined status reports Vercel FAILURE at https://vercel.com/prep-meds/prepmeds/9sEgUBSLranaYKmtCmiicd51dqcD; PR-triggered workflow lookup returned no runs. Previous block remains PARTIAL, not PASS. PR mergeable=false; underlying reason unverified.
- Attempted Vercel build-log retrieval for deployment ID 9sEgUBSLranaYKmtCmiicd51dqcD; Vercel connector returned 404 deployment not found in available scope, so failure cause remains unknown.
- Added direct negative-inheritance regression (7f7e0e4): two canonical IDs sharing one provisional ingredient set must retain NOT_STARTED clinical status, PENDING formulation adjudication, no source versions, and no last-reviewed date. This is a committed but NOT YET EXECUTED test.
- Last established inventory: 436 provisional mapped canonical IDs / 436 total, 233 provisional ingredient sets, 48 combination entries; final formulation-specific review-group denominator undetermined; 0 clinically completed groups, 0 clinically validated mappings, 0 completed ASGE comparisons. No clinical correction or patient-facing activation.
- Blockers: failed Vercel status with inaccessible logs, no verified CI for current head, formulation adjudication/static audit export incomplete, antithrombotic source comparisons pending.
- Next: recover scoped Vercel logs or run local build/test through authorized execution environment; address failed checks before merge, then static export and formulation splits.

## 2026-11-07 13:23 ET continuation — prior PARTIAL; opt-in static export added
- FIRST inspected prior ledger, PR #37 head 618eb5d (open, mergeable=false), previous negative tests, and commit combined status: Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/Bn2acfDw56A4v2vKDC7CUNT6ySyC). No passing CI evidence for previous block. PR #36 is closed; no assumption its behavior was fully validated.
- Added opt-in deterministic snapshot export to medication manifest Vitest suite (5987e06, newline fix adc9b92). Run from apps/web with `EXPORT_MEDICATION_AUDIT=1 pnpm exec vitest run tests/medication-validation-manifest.test.ts` to generate `docs/medication-audit-manifest.json`, then inspect and commit the generated JSON. This run DID NOT execute the command, generate JSON, or verify tests; static export remains PARTIAL.
- Last established baseline: 436 canonical IDs provisionally mapped, 233 provisional ingredient groups, 48 combination entries; final formulation-specific group denominator not established; 0 clinically reviewed groups, 0 clinically validated mappings, 0 ASGE comparisons. No medication clinical correction.
- Blockers: Vercel failure cause unverified; new commits untested; PR mergeable=false; no committed generated snapshot; clinical formulation adjudication/source review pending. Next: execute export and tests in authorized runner, commit snapshot, diagnose CI, then review antithrombotic source comparisons. No merge or patient-facing activation.

## 2026-11-07 14:23 ET continuation — previous PARTIAL; approval membership safety gate
- FIRST inspected PR #37 head 786cf0d, previous sprint ledger, manifest/export test, antithrombotic queue and approval gate. Prior Block 1 remains PARTIAL: static export unexecuted, formulation-specific denominator unadjudicated, no source comparisons.
- GitHub combined status for 786cf0d: Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/67xwfzuL4a8NBxa2NYNKLokTSRrX); PR-triggered workflow lookup returned zero runs. Retrieved Vercel project/team scope; direct deployment event lookup returned 404 NOT_FOUND, so root cause and current-head test outcomes remain UNVERIFIED.
- Identified approval-gate safety gap: a complete synthetic evidence fixture could be passed with an unrelated or nonexistent canonical medication/group. Added exact group-to-canonical-ID membership verification against discovered inventory (8213bf7) and negative regression fixtures for foreign IDs, fabricated groups, partial membership and empty IDs (c4c7d88). Tests COMMITTED, NOT EXECUTED; no clinical approvals conferred.
- Last established inventory: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets, 48 combination entries; clinically completed formulation-specific groups 0 / final denominator unknown; clinically validated canonical mappings 0/436; antithrombotic discovery 17 IDs/17 provisional groups; completed ASGE 2016 comparisons 0. This run: 0 clinical reviews, 0 clinical corrections.
- Blockers: unverified CI and inaccessible Vercel deployment logs; PR #37 mergeable=false; static audit snapshot not generated/committed; formulation adjudication and ASGE source comparisons pending. Next: execute current-head tests/build and export in authorized runner, diagnose Vercel scope/status, then reconcile source evidence. No merge or patient-facing activation.

## 2026-11-07 15:26 ET continuation — previous PARTIAL; snapshot drift protection
- FIRST inspected PR #37 head 5a4b495, prior sprint ledger, audit manifest/export test, antithrombotic audit queue and tests. GitHub combined status for previous head reports Vercel FAILURE (https://vercel.com/prep-meds/prepmeds/tD6x6Jexinziy8GN4ynWB5GSyoJF); workflow lookup returned zero runs. Previous block remains PARTIAL, not PASS.
- Fixed opt-in manifest export to compare byte-for-byte against an existing committed JSON snapshot and FAIL on drift rather than silently overwrite audit history (4c25928). When no snapshot exists, explicit opt-in still writes the initial file. Test committed, not executed; no passing CI claimed.
- Last established baseline: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets and 48 combination entries; clinically validated IDs 0/436, completed clinically distinct formulation groups 0 (final denominator unknown), antithrombotic discovery 17 IDs/17 provisional groups, ASGE comparisons 0. This run: 0 clinical reviews, 0 clinical corrections.
- Remaining: execute export and commit initial snapshot; verify current-head tests and Vercel build, diagnose PR mergeable=false, adjudicate formulation groups and reconcile original guideline evidence. No merge, signoff, or patient-facing activation.


## 2026-11-07 17:26 ET continuation — previous PARTIAL; inventory safety tests committed
- FIRST inspected previous sprint ledger, PR #45 head `e977e53` (OPEN), canonical manifest and antithrombotic audit queue. PR #37 has already merged; do not repeat its work. Previous Block 1 remains PARTIAL: no committed static snapshot, no final clinically distinct formulation denominator and no completed clinical review.
- Fixed manifest validation to reject blank canonical medication names (4b133438), preventing unreviewable inventory entries. Added negative-name and source-order-invariance regression tests (b1c1c47). Both changes are on the sprint branch; they do not change medication instructions.
- Latest commit combined GitHub status: PENDING with zero status contexts when checked. Tests/CI NOT VERIFIED; no claim of PASS. PR #45 remains separate/open and its tests must be verified before merge.
- Last established totals: 436/436 canonical IDs provisionally mapped; 233 provisional ingredient sets, 48 combinations; final formulation review-group denominator UNKNOWN; 0 clinically reviewed groups, 0 clinically validated canonical mappings; 17 discovered antithrombotic IDs, 0 completed ASGE 2016 comparisons. This run: 0 clinically completed groups, 0 medication clinical corrections.
- Blockers: static manifest snapshot not generated/committed, final formulation adjudication incomplete, source-by-source ASGE comparator incomplete, CI not yet verified on this head. Next: run manifest export and tests in CI runner, commit reviewed static snapshot, adjudicate distinct formulations and begin source-specific agent comparisons. No patient-facing activation.


## 2026-11-07 18:25 ET continuation — previous PARTIAL; immutable-ID integrity fix
- FIRST inspected sprint checklist, manifest builder, existing regression suite, and PR #45 (open, mergeable=true). Prior Block 1 remains PARTIAL because static snapshot export, formulation adjudication, and current-head CI are unfinished. Prior clinical comparisons remain zero.
- Rejected leading/trailing whitespace in immutable canonical medication IDs and ingredient IDs before grouping (49936ee); added three negative regression fixtures (0fa32da). These are data-integrity safeguards, not medication-specific clinical validation. Existing group assignment and patient-facing medication guidance were not changed.
- GitHub combined commit status for 0fa32da: PENDING, zero status contexts at inspection. New tests NOT VERIFIED as passing. No deployment claimed.
- Last verified baseline: 436/436 provisional ID mappings, 233 provisional ingredient sets, 48 combination entries; final formulation-specific denominator unknown; 0 clinically completed groups and 0 clinically validated IDs. Antithrombotic discovery 17 IDs, ASGE comparisons 0. This run: 0 clinical groups completed, 0 clinical medication corrections.
- NEXT: run CI for branch head, generate and commit static manifest using explicit export, then adjudicate formulation groups and source-specific antithrombotic comparisons. PR #45 is still open; no merge or clinical signoff.


## 2026-11-07 19:24 ET continuation — previous Block 1 PARTIAL; control-character integrity gate
- FIRST inspected prior 18:25 ET handoff, current manifest/export test, and PR #45 (open at e977e53); prior Block 1 acceptance remains PARTIAL because no committed static snapshot or formulation adjudication, and no clinical comparisons are complete.
- Added control-character rejection for immutable medication IDs, ingredient IDs, and canonical labels in manifest builder (8ec764f); added three negative regression scenarios for newline, NUL, and tab corruption (77376f9). These are engineering safeguards, not medication clinical reviews. The changes have NOT been executed or confirmed by CI during this run.
- Established baseline remains 436/436 provisional canonical-ID mappings, 233 provisional ingredient sets, 48 combinations; final formulation-specific denominator unknown; 0 clinically reviewed groups, 0 clinically validated IDs, 17 discovered antithrombotic IDs, and 0 completed ASGE comparisons. This run: 0 clinical reviews and 0 clinical corrections.
- Blockers: no verified test execution on new commits; static snapshot export and formulation adjudication still pending; source-specific ASGE 2016 reconciliation not complete. PR #45 remains open; no merge or patient-facing activation.
- NEXT: run Vitest and explicit static manifest export in a runner with repository checkout, commit verified snapshot, adjudicate formulation groups, then progress antithrombotic evidence. Do not count this integrity gate as clinical signoff.


## 2026-11-07 20:26 ET continuation — previous Block 1 PARTIAL; negative-test fixture repaired
- FIRST inspected the sprint checklist, PR #45 (OPEN at e977e53), manifest builder, export test, antithrombotic queue and prior handoff. Block 1 remains PARTIAL: static snapshot export not executed/committed and final formulation denominator unknown. No clinical source comparison has been completed.
- Found a **false-positive regression risk**: the three newly added control-character tests passed literal backslash sequences (`\\n`, `\\u0000`, `\\t`) rather than actual newline/NUL/tab characters. Corrected the fixtures to actual control-character escapes in commit `6f7b5584085a3d139be36e1c9060cb6d001f93e2`. This is test correctness work, not clinical review.
- New commit test execution and CI results are NOT established; no local runner or manifest export execution occurred in this run. Do not mark the new tests as passed or the snapshot as committed.
- Baseline (last established): 436/436 provisionally mapped canonical IDs, 233 provisional ingredient sets, 48 combination entries, 17 antithrombotic IDs; final clinically distinct formulation groups UNKNOWN; clinically reviewed groups 0, clinically validated IDs 0/436, completed ASGE comparisons 0. New clinical reviews 0, clinical corrections 0.
- NEXT: execute Vitest and explicit snapshot export in a runner, verify current-head CI, commit actual generated manifest, adjudicate formulation-specific splits and perform source-linked agent comparisons. No merge or patient-facing rule activation.
